AfricaRegulatory

African Pharmaceutical Regulatory Intelligence

RIFAMPICIN

13 registrations across 4 African markets— 10 active

Markets with RIFAMPICIN

Recent registrations

Brand / ProductMarketHolderStatusExpires
RIFAMPICIN
CAPSULE; ORAL
🇿🇼ZimbabweDATLABS PRIVATE LIMITEDactiveDec 2027
RIFADIN CAPSULES 300 mg🇿🇦South AfricaSanofi-Aventis South Africa (Pty) LtdsuspendedApr 2025
RIFADIN CAPSULES 150 mg🇿🇦South AfricaSanofi-Aventis South Africa (Pty) LtdsuspendedApr 2025
R-CIN SUSPENSION🇿🇦South AfricaACINO PHARMA (PTY) LTDsuspendedDec 2023
RIFAGEN 300 mg CAPSULES🇿🇦South AfricaAfriPharm South Africa (Pty) LtdactiveJan 1900
Rifampicin🌍WWMacleods Pharmaceuticals Ltdactive
Rifampicin🌍WWOlon S.p.A.active
Rifampicin🌍WWLupin Ltdactive
RIFAMPICIN
ORAL SOLID ORDINARY CAPSULES
🇺🇬UgandaCOSMOS LTDactive
Rifampicin🌍WWOlon S.p.A.active
RIFAMPICIN
ORAL SOLID ORDINARY CAPSULES
🇺🇬UgandaCOSMOS LTDactive
Rifampicin🌍WWHebei Xingang Pharmaceutical Co Ltdactive
Rifampicin🌍WWHebei Xingang Pharmaceutical Co Ltdactive

RIFAMPICIN in Africa — Regulatory Overview

RIFAMPICIN is registered across 4 African markets with 13 total product registrations on file. Data is sourced directly from official national drug regulatory authorities including WW, South Africa, Uganda, Zimbabwe. AfricaRegulatory refreshes this data daily from official government sources.

Of the 13 registrations, 10 (77%) are currently active. Regulatory affairs teams use AfricaRegulatory to track registration expiry dates, identify market incumbents, and monitor approval status across African markets without manual monitoring of each national regulator.